Dr. Fouad Chebib, MD

Dr. Chebib practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Dr. Chebib's NPI, 1235450602, was assigned on June 19, 2010. Dr. Chebib graduated from University of Balamand Faculty of Medicine in 2008. Dr. Chebib holds Florida license ME154401.

Dr. Chebib's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Dr. Chebib's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville. Dmand AI also links Dr. Chebib to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chebib practices. Vendor and product names are available with a free account.

Nephrology is Dr. Chebib's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Chebib is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Chebib's licenses on file in 4 states: Florida, Minnesota, Wisconsin and Massachusetts.

Dmand AI lists chronic kidney disease, fluid and electrolyte imbalances and hypercalcemia among the conditions Dr. Chebib treats.

CMS data shows 268 Medicare services from Dr. Chebib across 2 procedure codes in 2024, for 124 Medicare patients. Medicare paid $22,948 for them.

CMS counts 124 Medicare patients who saw Dr. Chebib in 2024. The largest group is 65 to 74, with 47 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. Their average risk score is 4.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chebib's median patient age at 57, with 58% women.

In 2024, Dr. Chebib wrote 99 Medicare Part D claims for 20 patients. 99% of them were for generic drugs. CMS names the drug for 41 of them, across 3 drugs with 11 or more claims each, at $239 in total drug cost. In 2023, CMS named 85 claims across 5 drugs.

Dr. Chebib accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chebib as offering telehealth.

Dmand AI links 89 papers to Dr. Chebib, published from 2009 to 2025. 2023 was the busiest year, with 13. The most frequent topics are Polycystic Kidney, Autosomal Dominant, Kidney and Disease Progression. Dr. Chebib has published most often in Kidney360. Dr. Chebib's most frequent co-authors are Vicente E. Torres, MD, Christian Hanna, MD and Neera Kanhouwa Dahl, MD.

Dmand AI links Dr. Chebib to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Diabetes Insipidus, Nephrogenic and Diabetes Insipidus.

CMS Open Payments shows 85 general payments to Dr. Chebib from 9 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 56% of the total. Otsuka Pharmaceutical Co., Ltd. paid the most, $45,223.

Dr. Chebib serves on PKD foundation- Educational Advisory Panel.

Dr. Chebib graduated from University of Balamand Faculty of Medicine in 2008. Dr. Chebib is a member of ASN.

Dr. Chebib is in network with 9 carriers, including Aetna, Elevance and United Healthcare. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.